The data from this prospective cohort study confirm and expand previous retrospective case series that have found factors, including hematologic cancers, chemotherapy receipt, and lung cancer, as ...

While the accelerated approval pathway has enabled faster access to promising oncology drugs, meaningful improvements in survival or quality of life often remain unproven, even after full approval,” ...